US M&A and equity raisings

3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

Deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

13 deals · US$2.9bndisclosed · Oncology · Clear

Columns
US M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Dec 2025 Freenome ––PlacementCompleted240.0Diagnostics+2 Goodwin (issuer)Jefferies (lead manager)Leerink Partners (lead manager)White & Case (lead manager)
Jan 2026 Aktis Oncology ––IPOListed317.7Biotech+2 Paul Hastings (issuer)Goodwin (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Davis Polk (lead manager)
Feb 2026 Perspective Therapeutics ––Follow-on offeringAnnounced175.0Radiopharmaceuticals+2 Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager)LifeSci Capital (lead manager)
Feb 2026 Eikon Therapeutics ––IPOAnnounced381.2Oncology+1 Covington & Burling (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)BofA Securities (lead manager)Cantor Fitzgerald (lead manager)Mizuho Securities (lead manager)Davis Polk (lead manager)
Feb 2026 Liminatus Pharma ––Follow-on offeringAnnounced4.0Biotech+2 Loeb & Loeb (issuer)Maxim Group (lead manager)Lucosky Brookman (lead manager)
Feb 2026 Sensei Biotherapeutics ––PlacementPending200.0Biotech+2 Cantor Fitzgerald (issuer)Citi (issuer)Sidley Austin (issuer)Leerink Partners (lead manager)
Apr 2026 Obsidian Therapeutics ––PlacementCompleted350.0Biotech+2 GoodwinSidley Austin (issuer)Leerink Partners (lead manager)TD Securities (lead manager)Piper Sandler (lead manager)William Blair (lead manager)LifeSci Capital (lead manager)Mintz (lead manager)
Jun 2026 Avenzo Therapeutics ––PlacementPending215.0Biotech+2 Leerink Partners (lead manager)Goldman Sachs (lead manager)Piper Sandler (lead manager)Guggenheim Securities (lead manager)Mintz (lead manager)
Jun 2026 Parabilis Medicines ––IPOListed670.0Biotech+2 Goodwin (issuer)Leerink Partners (lead manager)BofA Securities (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager)Covington & Burling (lead manager)
Jun 2026 Remix Therapeutics ––PlacementPending100.0Biotech+2 Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Cooley (lead manager)
Aug 2026 BlossomHill Therapeutics ––IPOListed150.0Biotech+2 Cooley (issuer)J.P. Morgan (lead manager)Leerink Partners (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager)H.C. Wainwright & Co. (lead manager)Latham & Watkins (lead manager)
Sep 2026 Pyxis Oncology ––Follow-on offeringAnnounced110.0Biotech+1 Latham & Watkins (lead manager)
– Silexion Therapeutics Corp ––Follow-on offeringAnnounced2.5Biotech+2 Conyers (issuer)Greenberg Traurig (issuer)H.C. Wainwright & Co. (lead manager)Ellenoff Grossman & Schole (lead manager)

Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built